Literature DB >> 14558001

Effect of conversion from cyclosporine A to mizoribine on transplant arteriosclerosis in rat aortic allograft models.

Hisashi Shimizu1, Masafumi Takahashi, Shinichi Takeda, Kazunori Tahara, Seiichiro Inoue, Yoji Hakamata, Takashi Kaneko, Izumi Takeyoshi, Yasuo Morishita, Eiji Kobayashi.   

Abstract

Recent studies suggested that conversion from cyclosporine A (CsA) to antimetabolic agents protects allograft vasculopathy. However, the mechanism of this beneficial effect by the conversion therapy is not fully understood. In the present study, we investigated the effects of conversion from CsA to antimetabolic agent mizoribine (MZR) on the formation of transplant arteriosclerosis in rat aortic allografts. Conversion from CsA to MZR significantly prevented intimal hyperplasia and perivascular inflammatory cell infiltration at 28 days after aortic transplantation. These findings suggest that conversion therapy from CsA to antimetabolic agents might have therapeutic potential in transplant patients with chronic vascular rejection. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14558001     DOI: 10.1002/micr.10171

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  4 in total

1.  A novel multidrug therapy for difficult cyclosporine-resistant focal segmental glomerulosclerosis.

Authors:  Eishin Oki; Kazushi Tsuruga; Masanobu Kudo; Koji Tsugawa; Koichi Suzuki; Hiroshi Tanaka
Journal:  Pediatr Nephrol       Date:  2008-10-24       Impact factor: 3.714

Review 2.  Treatment of young patients with lupus nephritis using calcineurin inhibitors.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Tomomi Aizawa-Yashiro; Shojiro Watanabe; Tadaatsu Imaizumi
Journal:  World J Nephrol       Date:  2012-12-06

Review 3.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

4.  Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome.

Authors:  Tomomi Aizawa-Yashiro; Kazushi Tsuruga; Shojiro Watanabe; Eishin Oki; Etsuro Ito; Hiroshi Tanaka
Journal:  Pediatr Nephrol       Date:  2011-04-09       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.